Enzyme immunoassay--a new technique for estimating hemoglobin A1c

Area of Science:

• Clinical Chemistry
• Immunology
• Biochemistry

Background:

• Glycated hemoglobin (HbA1c) is a crucial biomarker for long-term glycemic control in diabetes management.
• Accurate and precise measurement of HbA1c is essential for effective diabetes diagnosis and monitoring.
• Existing methods for HbA1c determination may have limitations in terms of cost, complexity, or interferences.

Purpose of the Study:

• To develop and validate a novel enzyme immunoassay (EIA) method for quantifying hemoglobin A1c (HbA1c).
• To assess the precision, linearity, and correlation of the new EIA method with established glycohemoglobin assays.
• To establish a reference interval for HbA1c in a nondiabetic population using the developed method.

Main Methods:

• Utilized a commercially available enzyme immunoassay system based on microtiter plate technology.
• Employed an antibody specific to the Amadori product of glucose on hemoglobin's N-terminal beta chain.
• Evaluated assay performance including within-batch and between-batch precision, linearity, and correlation with established methods.

Main Results:

• The EIA method demonstrated excellent precision (CV 2.3-5.0%) and linearity across the expected HbA1c range.
• High correlation (r = 0.88-0.98) was observed between the new method and established glycohemoglobin assays.
• A reference interval of 2.8-4.9% for HbA1c was established in a nondiabetic population.
• Diabetic individuals showed significantly higher HbA1c percentages (6.86% +/- 2.51%) compared to nondiabetics (3.46% +/- 0.52%).

Conclusions:

• The developed enzyme immunoassay provides a precise and reliable method for estimating HbA1c.
• This method is suitable for routine clinical laboratory use, offering accurate glycohemoglobin measurements.
• The findings support the utility of this EIA for differentiating between diabetic and nondiabetic individuals based on HbA1c levels.